<DOC>
	<DOC>NCT00805012</DOC>
	<brief_summary>To assess response rate of docetaxel and S-1 combination in metastatic or recurrent head and neck squamous cell carcinoma</brief_summary>
	<brief_title>Docetaxel and S-1 in Head and Neck Squamous Cell Carcinoma (HNSCC)</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Squamous Cell</mesh_term>
	<mesh_term>Head and Neck Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>histologically confirmed HNSCC adequate primary site: oral cavity, oropharynx, hypopharynx, nasal cavity, paranasal sinus, other head and neck site (except nasopharynx) at least one measurable lesion no previous palliative chemotherapy (adjuvant/neoadjuvant chemotherapy and/or radiotherapy longer than 6 months ago is permitted) 18 years or older ECOG 0 or 1 adequate laboratory result written, informed consent pregnant or lactating women (negative pregnancy test within 7 days is required for women with potential of childbearing) experimental drug clinical trial within 30 days other malignancy (exemption: treated basal cell carcinoma of skin, CIS, cured cancer with diseasefree interval with more than 5 years) patient with organ transplantation grade 2 or more peripheral neuropathy grade 2 or more hearing loss severe, medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>S-1</keyword>
	<keyword>docetaxel</keyword>
	<keyword>head and neck cancer</keyword>
	<keyword>Recurrent or metastatic head and neck squamous cell carcinoma</keyword>
</DOC>